Aeluma, Inc. Form 8-K Summary
Business Context and Reporting Date
Aeluma, Inc. filed a Current Report on Form 8-K dated May 11, 2023, reporting the final closing of a private equity offering and related registration rights and placement-agent arrangements. The company is incorporated in Delaware and is an emerging growth company.
Offering and Key Financial Metrics
- The offering was completed through multiple closings at $3.00 per share.
- Total gross proceeds were $6,052,500, representing the maximum offering amount.
- The final closing on May 10, 2023 generated gross proceeds of $1,710,500 from the issuance of 570,166 shares.
- Earlier closings generated $1,551,000, $644,000, and $2,147,000, respectively.
- The company paid a $136,840 cash placement-agent fee for the final closing.
- The company will issue placement-agent warrants to purchase up to 44,933 shares at an exercise price of $3.00 per share.
- The filing does not provide revenue, profit, cash flow, margin, debt, cash balance, liquidity, or other operating-performance metrics.
Material Changes and Transaction Terms
The offering is now closed after reaching its maximum size. The filing states that an aggregate of 517,0000 shares was issued in the initial closing; this share count appears unclear or typographical because the stated $1,551,000 proceeds at $3.00 per share imply 517,000 shares.
The securities were sold in an unregistered offering to accredited investors in reliance on Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. The company agreed to register the shares issued in the offering, including shares underlying the placement-agent warrant.
Outlook, Risks, and Unusual Items
- No financial guidance or operating outlook was provided.
- The shares and warrants were not registered under the Securities Act and may not be resold in the United States absent registration or an applicable exemption.
- The transaction creates potential future dilution from the placement-agent warrants and from the shares sold in the offering.
- The subscription agreements contain customary representations, warranties, indemnification obligations, termination provisions, and related investor rights.
Investor Verification Items
- Verify the initial-closing share count, which is presented ambiguously as “517,0000” in the filing.
- Confirm the final number of shares issued across all closings and the resulting fully diluted share count.
- Review the registration rights agreement and the terms of the placement-agent warrants.
- Assess the company’s use of the $6,052,500 gross proceeds and its cash needs in subsequent filings.
- Confirm the impact of offering-related dilution and placement-agent fees on shareholders.